NanoVibronix (NAOV) stock has been one of the most important gainers over the past weeks. However, at the same time, it should even be noted that the stock has been quite volatile. After having hit record highs recently of 17.65%, the stock slumped by the maximum amount of 9.91%. That being said, the NanoVibronix stock continues to be up by a staggering 140.96% since January and hence, it would still be a decent idea for investors to stay an eye fixed on the stock. The stock had rallied strongly earlier this month after the corporate announced that it signed a licensing pander to Oncology Pharma for its carcinoma treatment. NanoVibronix has released the findings of a randomized, double-blind trial that assessed the NanoVibronix PainShield’s safety and efficacy.
An orthopedic surgeon was treating the patients within the research. Tennis elbow patients, swelling or ripping of the tendons within the arm, were treated within the research. All of the patients had followed the quality therapy protocol, which had did not offer pain relief within the PainShield treatment group, 91% of patients saw total or partial symptom relief. PainShield was utilized in conjunction with over-the-counter medications but without the advantage of the opioid-based ethical drugs.